Risks versus benefits of different types of long-acting injectable antipsychotics

Journal of Clinical Psychiatry

Volumn 67, Issue SUPPL. 5, 2006, Pages 15-18

  McEvoy, Joseph P ^a,b  

^a John Umstead Hospital   (United States)

^b DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; FLUPHENAZINE DECANOATE; HALOPERIDOL DECANOATE; LONG ACTING DRUG; NEUROLEPTIC AGENT; RISPERIDONE; SHORT ACTING DRUG;

COST BENEFIT ANALYSIS; DISEASE EXACERBATION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG HALF LIFE; DRUG USE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; INJECTION SITE DISCOMFORT; INJECTION SITE IRRITATION; INJECTION SITE PAIN; INJECTION SITE REACTION; MOTOR DYSFUNCTION; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; QUALITY OF LIFE; RECURRENCE RISK; RELAPSE; REVIEW; RISK ASSESSMENT; SCHIZOPHRENIA; TARDIVE DYSKINESIA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; ANTIPSYCHOTIC AGENTS; FLUPHENAZINE; HALOPERIDOL; HEALTH CARE COSTS; HUMANS; INJECTIONS, INTRAMUSCULAR; MICROSPHERES; QUALITY OF LIFE; RECURRENCE; RISK ASSESSMENT; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT REFUSAL;

EID: 33744793769     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Ayd FJ. The depot fluphenazines: a reappraisal after 10 years' clinical experience. Am J Psychiatry 1975;132:491-500
2. Johnson DAW. Practical considerations in the use of depot neuroleptics for the treatment of schizophrenia. Br J Hosp Med 1977;17:546-558
3. Adams CE, Fenton MKP, Auraishi S, et al. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 2001;179:290-299
4. Kane JM, Aguglia E, Altamura AC, et al. Guidelines for depot antipsychotic treatment in schizophrenia: European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol 1998;8:55-66
5. Deneker SJ, Axelsson R. Optimizing the use of depot antipsychotics. CNS Drugs 1996;6:367-381
6. Barnes TRE, Curson DA. Long term depot antipsychotics: a risk-benefit assessment. Drug Saf 1994;10:464-479
7. Weiden P, Rapkin B, Zygmut A, et al. Postdischarge medication compliance of inpatients converted from an oral to a depot neuroleptic regimen. Psychiatr Serv 1995;46:1049-1054
8. Altamura AD, Tucchini GL, Maes M. Haloperidol plasma " threshold" levels for relapse prevention in schizophrenia: a study with haloperidol decanoate. Eur Neuropsychopharmacol 1995;5:55-58
9. Ereshefsky L, Saklad SR, Jann MW, et al. Future of depot neuroleptic therapy: pharmacokinetic and pharmacodynamic approaches. J Clin Psychiatry 1984;45(5, sec 2):50-59
10. Babiker IE. Comparative efficacy of long-acting depot and oral neuroleptic medication in preventing schizophrenic recidivism. J Clin Psychiatry 1987;48:94-97
11. David A, Adams CE, Eisenbruch M, et al. Depot fluphenazine decanoate and enanthate for schizophrenia. Cochrane Database Syst Rev 2005;1: CD000307
12. Chouinard G, Annable L, Campbell W. A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia. J Clin Psychopharmacol 1989;9:247-253
13. 2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000;157:514-520
14. Starmark JE, Foreman A, Wahlstrom J. Abscesses following prolonged intramuscular administration of perphenazine enanthate. Acta Psychiatr Scand 1980;62:154-157
15. Davis JM, Metalon L, Watanabe MD, et al. Depot antipsychotic drugs: place in therapy. Drugs 1994;47:741-773. Correction 1994;48:616
16. Froemming JS, Lam YW, Jann MW, et al. Pharmacokinetics of haloperidol. Clin Pharmacokinet 1989;17:396-423
17. Risperdal Consta [package insert]. Titusville, NJ: Janssen Pharmaceutica; 2005
18. Kane JM, Eerdekens M, Lindenmayer J-P, et al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003;160:1125-1132
19. Lasser RA, Ramstack JM, Grandolfi GP, et al. Long-acting injectable risperidone (Risperdal Consta): manufacture using Medisorb microsphere technology, pharmacokinetics, and injection-site assessments [poster]. Presented at the 155th annual meeting of the American Psychiatric Association; May 18-23, 2002; Philadelphia, Pa
20. Eerdekens M, Fleischhacker WW, Xie Y, et al. Long-term safety of long-acting risperidone microspheres [abstract]. Schizophr Res 2002;53(suppl 3):174
21. Ereshefsky L, Toney G, Saklad SR, et al. A loading-dose strategy for converting from oral to depot haloperidol. Hosp Community Psychiatry 1993;44:1155-1161
22. Gefvert O, Eriksson B, Persson P, et al. Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. Int J Neuropsychopharmacol 2005;8:27-36